• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zimmer Biomet Highlights Diverse Portfolio of Orthopedic & Musculoskeletal Innovations at AAOS 2025 Annual Meeting

    3/10/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care
    Get the next $ZBH alert in real time by email

    Booth Spotlights Comprehensive Hip Portfolio, Newly Launched Knee and Upper Extremities Reconstructive Technologies, Including Recently Cleared Persona® Revision SoluTion™ Femur, and Debut of ZBX™ Ambulatory Surgery Center Solutions

    WARSAW, Ind., March 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting its diverse portfolio of orthopedic and musculoskeletal innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting being held March 10-14 in San Diego. During the meeting, the Company's booth will prominently feature its comprehensive hip portfolio, anchored by the new Z1™ Triple-Taper Femoral Hip System, along with the latest technologies for knee and upper extremity reconstruction and key components from its robotic solutions. In addition, Zimmer Biomet is debuting ZBX™, its new Ambulatory Surgery Center (ASC) offering to surgeons and institutions looking to expand their orthopedic footprint.

    (PRNewsfoto/Zimmer Biomet Holdings, Inc.)

    "I am thrilled to showcase the collective strength and broad range of our musculoskeletal portfolio, including the introduction of several recently cleared technologies, at this year's annual AAOS meeting," said Ivan Tornos, President and Chief Executive Officer at Zimmer Biomet. "We are in the midst of one of the largest innovation cycles in our company's history. Our broad hip reconstruction portfolio combined with our comprehensive knee portfolio with constructs designed to safeguard against cement and metal sensitivities, our bone-preserving stemless shoulder and now an enhanced suite of ASC solutions, squarely position us at the forefront of delivering customer-centric innovations to improve efficiency and overall patient outcomes."

    The highlights at the Zimmer Biomet booth (#3129) include:

    Hip Reconstruction Technologies

    • Z1™ Femoral Hip System, a triple-taper design with expansive innovations within a more comprehensive system, providing more solutions to treat more patients.
    • HAMMR® Automated Hip Impaction System, designed to address surgeon strain, fatigue and repetitive motion associated with traditional mallet use during bone preparation and device implantation.
    • OrthoGrid Hip AI®, an AI-powered, fluoroscopy-based technology that provides direct anterior (DA) hip surgeons with intuitive and instantaneous intra-operative tools to assist surgeons in achieving the desired surgical outcomes for component positioning.1
    • HipInsight™ System, the first FDA-cleared mixed reality system for hip navigation offers intuitive, intra-operative guidance that leverages the Microsoft HoloLens 2 (mixed reality headset) to help visualize and guide accurate2 acetabular component placement and alignment in real-time.

    Knee Reconstruction Technologies

    • Persona® Revision SoluTion™ Femur, a newly cleared revision knee implant component, part of the comprehensive Persona Revision Knee System, offering an alternative to cobalt-chrome (Co-Cr-Mo) alloy for patients with sensitivities to certain metals.
    • Oxford® Cementless Partial Knee, the only FDA-approved cementless partial knee implant in the U.S. that has been shown to be efficient3,4 in the OR, and has been proven to have excellent longevity5,6 worldwide.
    • Persona® OsseoTi® Keel Tibia, a cementless anatomic tibia with a 3D printed porous tray from our clinically proven Persona Knee System5-7 designed to deliver stable initial and biological fixation and intra-operative versatility.8
    •  Persona IQ® 30 mm Stem, the world's only smart knee implant, now in a 30 mm stem length, that collects data directly from the knee to provide post-operative recovery insights9,10 and trends, allowing care teams to monitor and personalize the total knee arthroplasty patient experience9-11 with the goal of improving practice efficiency.12-15

    Upper Extremities Technology

    • OsseoFit™ Stemless Shoulder System, an anatomically shaped,16-18 asymmetric stemless shoulder implant designed for stable initial19-22 and biological fixation23, 24 by optimizing anatomic humeral fit for stemless shoulder arthroplasty.

    ASC Solutions

    • ZBX, Zimmer Biomet's new comprehensive ASC program offering surgeons an experienced partner to strategically incorporate solutions, unique to each surgeon's needs, providing efficiency in the OR and beyond.

    For more information about Zimmer Biomet events at AAOS 2025, visit www.zimmerbiomet.com/academy2025. 

    Important Safety Information for Oxford Cementless Partial Knee:

    The Oxford® Cementless Partial Knee System is indicated for use in unilateral knee procedures with osteoarthritis or avascular necrosis limited to the medial compartment of the knee. It is intended to be implanted without the application of bone cement for patients whose clinical condition would benefit from a shorter surgical time compared to the cemented implant. The Oxford Partial Knee Is not indicated for use in the lateral compartment or for patients with ligament deficiency, or for use in simultaneous bilateral surgery or planned staged bilateral procedures. Potential risks include, but are not limited to, loosening, dislocation, fracture, wear and infection, any of which can require additional surgery. For a full list of product indications, contraindications and warnings, please see the associated product Instructions For Use (IFU).

    About Zimmer Biomet

    Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. 

    With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

    For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.x.com/zimmerbiomet. 

    Cautionary Statement Regarding Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the Company's expectations, plans, intentions, strategies, prospects, business plans, product and service offerings, new product launches, potential clinical successes, and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

    References:

    1. Cardenas JM, Gordon D, Waddell BS, Kitziger KJ, Peters PC Jr, Gladnick BP. Does Artificial Intelligence Outperform Humans Using Fluoroscopic-Assisted Computer Navigation for Total Hip Arthroplasty? Arthroplasty Today. 2024 May 27;27:101410. doi: 10.1016/j.artd.2024.101410. PMID: 38840694; PMCID: PMC11150909.  
    2. Dilbone ES, Heimann AF, Leal J, Ryan SP, Wellman SS. Evaluating the Accuracy of a Computed Tomography-Based Mixed-Reality Navigation Tool for Acetabular Component Positioning in Total Hip Arthroplasty. The Journal of Arthroplasty. 2025.
    3. Pandit, H., et al. "Improved fixation in cementless unicompartmental knee replacement: five-year results of a randomized controlled trial." JBJS 95.15 (2013): 1365-1372.
    4. Stempin R, Kaczmarek W, Stempin K, Dutka J. Midterm Results of Cementless and Cemented Unicondylar Knee Arthroplasty with Mobile Meniscal Bearing: A Prospective Cohort Study. Open Orthop J. 2017 Oct 31;11:1173-1178. doi: 10.2174/1874325001711011173. PMID: 29290853; PMCID: PMC5721307
    5. NJR-UK. The National Joint Registry 21st Annual Report 2024 London, 2024 [Available from: https://reports.njrcentre.org.uk/Portals/0/PDFdownloads/NJR%2021st%20Annual%20Report%202024_Knees.pdf.
    6. AOANJRR. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2023 Annual Report Adelaide, AOA2024 [updated 2024. Available from: https://aoanjrr.sahmri.com/documents/10180/1798900/AOANJRR+2024+Annual+Report.pdf/9d0bfe03-2282-8fc8-a424-b8d9abb82b1f?t=1727666185313.
    7. American Joint Replacement Registry (AJRR): 2024 Annual Report. Rosemont, IL: American Academy of Orthopaedic Surgeons (AAOS), 2024. https://www.aaos.org/registries/publications/ajrr-annual-report/#:~:text=When%20citing%20any%20Annual%20Report,at%20RegistryEngagement%40aaos.org

      National Joint Registry of England, Wales, Northern Ireland, the Isle of Man and Guernsey. 20th Annual Report 2023
    8. Mueller JK, et al. Persona OsseoTi Keel Tibia Provides Stable Initial Fixation 4027.2-GLBL-en. November 2022
    9. Cushner FD, Yergler J, ElashoffB, Aubin PM, VertaP, Scuderi GR. Staying Ahead of the Curve: The Case for Recovery Curves in Total Knee Arthroplasty. The Journal of Arthroplasty. 2024;doi:10.1016/j.arth.2024.07.039
    10. Cushner FD, Sculco PK, Long WJ. The Talking Knee Is a Reality: What Your Knee Can Tell You After Total Knee Arthroplasty. J OrthopaedicExperience and Innovation. 2022;2022
    11. Cushner FD, Schiller P, Gross J, Mueller JK, Hunter W. A TOTAL KNEE ARTHROPLASTY PROSTHESIS CAPABLE OF REMOTE PATIENT MONITORING. OrthopaedicProceedings. 2021/06/01 2021;103-B(SUPP_9):18-18 doi:10.1302/1358-992X.2021.9.018
    12. Yocum DS, Redfern RE, Yergler JD. Delayed Recovery Following Total Knee Arthroplasty Identified by Remote Monitoring With Tibial Extension Sensors. Arthroplasty Today. 2023/10/01/ 2023;23:101188. doi: https://doi.org/10.1016/j.artd.2023.101188
    13. Yocum D, HousholderE, Yergler J. Manipulation under Anesthesia Following TKA with Persona IQ: A Case Series. J OrthopCase Rep. Aug 2023;13(8):127-131. doi:10.13107/jocr.2023.v13.i08.3844
    14. Dundon J, Aubin P, Hunter W. Objective Gait Analysis Following Total Knee Arthroplasty with a Smart Implant Directs Early Intervention with Manipulation under Anesthesia. Journal of OrthopaedicExperience & Innovation. 2024;Februarydoi:https://doi.org/10.60118/001c.89961.
    15. Parikh N, Redfern R, Yocum D, Andel D V, Yergler J. MT46 Patient Experience and Outcomes with Post-Surgical Remote Monitoring for Patients with Total Knee Arthroplasty (TKA). Value in Health. 2024/06/01/ 2024;27(6, Supplement):S290. doi:https://doi.org/10.1016/j.jval.2024.03
    16. Mueri, C, Snethen, K, Parisi, R, Son, Yang, Duquin, T Characterization of the Asymmetric Bone Envelope of the Proximal Humeral Metaphysis for Stemless Shoulder Implants. ORS Orthopaedic Research Society 2025 Annual Meeting, Paper No. 1175; 2025 Feb 7-11; Phoenix, Arizona.
    17. Son, Y, Mueri, C, Snethen, K, Bowman, L, Parisi, R, Duquin, T Optimizing Stemless Humeral Anchors: Asymmetrical Designs for Minimizing Cortical Bone Impingement while Maximizing Cancellous Bone Purchase. ORS Orthopaedic Research Society 2025 Annual Meeting, Paper No. 2051; 2025 Feb 7-11; Phoenix, Arizona.
    18. ZRR_WI_6743_24. Analysis of Potential Cortical Perforation for the OsseoFit Stemless Shoulder. Zimmer Biomet Internal Research Report on File.
    19. Snethen, K, Mueri, C, Kriska, T, Son, Y, Bandi, M The Sensitivity of the Stability of Stemless Humeral Implants to Surgical, Patient and Design Factors in Reverse Shoulder Arthroplasty. Presented at the ORS Orthopaedic Research Society Annual Meeting; 2023, Dallas, Texas.
    20. Snethen, K, Son, Y, Mueri, C, Bischoff, J The Effect of Press-fit on Initial Stability in Stemless Shoulder Arthroplasty. Presented at the ISTA International Society for Technology in Arthroplasty Annual Meeting; 2022, Maui, Hawaii.
    21. Snethen, K, Mueri, C, Son, Y, Parisi, R, Duquin, T The Effect of Geometric Design on Initial Stability of Stemless Shoulder Implants. ORS Orthopaedic Research Society 2025 Annual Meeting, Paper No. 1168; 2025 Feb 7-11; Phoenix, Arizona.
    22. ZBTR_30118. Anchor-Level Micromotion of the OsseoFit Stemless Shoulder with Application in Anatomic Total Shoulder Arthroplasty. Zimmer Biomet Internal Design Verification Report on File.
    23. Gupta, G Evaluation of Bony Ingrowth Implant Materials in an In Vivo Sheep Long Bone Defect Model 12-04/12-07, February 2013. 32.
    24. Gupta, G OsseoTi Porous Metal For Enhanced Bone Integration: an Animal Study. White Paper. 2014. Form No. BMET0718.0-GBL • REV1214.

    Laboratory and animal studies are not necessarily indicative of clinical performance.

    HipInsight™ System is a trademark of Surgical Planning Associates, Inc.

    Microsoft and HoloLens 2 are trademarks of the Microsoft Corporation.

    Persona IQ: The objective kinematic data generated by the Canary Canturio® Tibial Extension with CHIRP® System are not intended to support clinical decision-making and have not been shown to provide any clinical benefit.

    345 E. Main St.

    Warsaw, IN 46580

    www.zimmerbiomet.com    

    Media

    Investors

    Heather Zoumas-Lubeski

    David DeMartino

    445-248-0577

    646-531-6115

    [email protected]

    [email protected] 

    Kirsten Fallon

                   Zach Weiner

    781-779-5561

                   908-591-6955

    [email protected] 

                   [email protected]  

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-highlights-diverse-portfolio-of-orthopedic--musculoskeletal-innovations-at-aaos-2025-annual-meeting-302396091.html

    SOURCE Zimmer Biomet Holdings, Inc.

    Get the next $ZBH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZBH

    DatePrice TargetRatingAnalyst
    3/23/2026Buy → Neutral
    BTIG Research
    2/20/2026Mkt Perform
    William Blair
    1/9/2026$93.00Neutral → Sell
    Goldman
    1/6/2026Outperform → Mkt Perform
    Raymond James
    1/5/2026$210.00In-line → Outperform
    Evercore ISI
    12/16/2025$100.00Outperform → Neutral
    Robert W. Baird
    11/6/2025$100.00Overweight → Neutral
    Analyst
    9/18/2025$130.00Buy
    Rothschild & Co Redburn
    More analyst ratings

    $ZBH
    SEC Filings

    View All

    SEC Form DEFA14A filed by Zimmer Biomet Holdings Inc.

    DEFA14A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    4/1/26 7:03:16 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form DEF 14A filed by Zimmer Biomet Holdings Inc.

    DEF 14A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    4/1/26 7:00:44 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Zimmer Biomet Holdings Inc.

    SCHEDULE 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    3/27/26 2:15:50 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zimmer Biomet downgraded by BTIG Research

    BTIG Research downgraded Zimmer Biomet from Buy to Neutral

    3/23/26 8:28:29 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    William Blair initiated coverage on Zimmer Biomet

    William Blair initiated coverage of Zimmer Biomet with a rating of Mkt Perform

    2/20/26 8:25:46 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet downgraded by Goldman with a new price target

    Goldman downgraded Zimmer Biomet from Neutral to Sell and set a new price target of $93.00

    1/9/26 8:52:52 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results

    WARSAW, Ind., April 9, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its first quarter earnings conference call will be webcast on Tuesday, April 28, 2026, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call.Individuals in the U.S. and Canada who wish to dial int

    4/9/26 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer

    Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacityWARSAW, Ind., April 7, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Jonathan M. Vigdorchik, M.D., as Chief Science, Technology and Medical Affairs Officer, effective April 14. In this role, Dr. Vigdorchik will oversee the strategy, delivery, and management of the company's global end-to-end technology portfolio, including AI,

    4/7/26 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet to Release New Data, Highlight Key Innovations at American Academy of Orthopaedic Surgeons Annual Meeting

    Company's Chief Movement Officer, Arnold Schwarzenegger,Will Be Presidential Guest SpeakerWARSAW, Ind., Feb. 25, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced it will unveil new clinical and operational data and showcase its newest innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting. The company's Chief Movement Officer Arnold Schwarzenegger will take center stage as the conference's Presidential Guest Speaker. On Thursday, March 5 at 10:30 a.m. Central Time, Schwarzen

    2/25/26 7:06:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jafry Syed A. bought $223,641 worth of shares (2,135 units at $104.75), increasing direct ownership by 111% to 4,060 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    11/13/23 4:02:02 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Begley Christopher B bought $117,114 worth of shares (1,000 units at $117.11), increasing direct ownership by 39% to 3,540 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    9/29/23 4:05:41 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Noor Jehanzeb

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    4/3/26 4:03:16 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Jafry Syed A.

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    4/2/26 4:20:40 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Kolli Sreelakshmi

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    4/2/26 4:19:52 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Leadership Updates

    Live Leadership Updates

    View All

    Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer

    Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacityWARSAW, Ind., April 7, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Jonathan M. Vigdorchik, M.D., as Chief Science, Technology and Medical Affairs Officer, effective April 14. In this role, Dr. Vigdorchik will oversee the strategy, delivery, and management of the company's global end-to-end technology portfolio, including AI,

    4/7/26 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces New Chief Medical Advisors to Help Improve Standard of Musculoskeletal Care

    Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.) WARSAW, Ind., Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand M. Murthi, MD, FAAOS, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.). As strategic advisors, Drs. Vigdorchik and Murthi will leverage their extensive clinical experience t

    8/28/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

    WARSAW, Ind., May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Mr. Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and execution for its global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units. "Kevin is an incredible addition to our leadership team at an e

    5/27/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Financials

    Live finance-specific insights

    View All

    Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results

    WARSAW, Ind., April 9, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its first quarter earnings conference call will be webcast on Tuesday, April 28, 2026, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call.Individuals in the U.S. and Canada who wish to dial int

    4/9/26 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2026

    WARSAW, Ind., Feb. 23, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2026. The cash dividend of $0.24 per share is payable on or about April 30, 2026 to stockholders of record as of the close of business on March 31, 2026. About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamles

    2/23/26 7:00:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Fourth Quarter and Full-Year 2025 Financial Results

    Fourth quarter net sales of $2.244 billion increased 10.9% on a reported basis, 9.2% on a constant currency1 basis and 5.4% on an organic constant currency1 basisFourth quarter diluted earnings per share were $0.70, a decrease of 41.7%; adjusted1 diluted earnings per share were $2.42, an increase of 4.8%Full-year net sales of $8.232 billion increased 7.2% on a reported basis, 6.4% on a constant currency1 basis and 3.9% on an organic constant currency1 basisFull-year diluted earnings per share were $3.55, a decrease of 19.9%; adjusted1 diluted earnings per share were $8.20, an increase of 2.5%Company provides full-year 2026 financial guidanceWARSAW, Ind., Feb. 10, 2026 /PRNewswire/ -- Zimmer

    2/10/26 6:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/14/24 1:22:34 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc.

    SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/13/24 1:44:56 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    2/14/24 10:02:59 AM ET
    $ZBH
    Industrial Specialties
    Health Care